In which condition is Hetastarch (Hespan) contraindicated?

In which condition is Hetastarch (Hespan) contraindicated?

• A. Coagulopathy
• B. Dehydration
• C. Postoperative recovery
• D. Hypotension

Answer: (A)

Hetastarch, also known as Hespan, is a volume expander that is often used in situations requiring plasma volume expansion. However, it is contraindicated in patients with coagulopathy because it can impair normal blood clotting mechanisms. Coagulopathy refers to a condition in which the blood’s ability to clot is severely reduced, leading to an increased risk of bleeding. When administering Hetastarch in such patients, there is a significant risk that the medication could exacerbate bleeding complications by further interfering with coagulation processes. The synthetic colloid effect of Hetastarch can dilute clotting factors or interfere with platelet function, creating a hazardous situation for individuals already susceptible to bleeding due to an underlying coagulopathy. In contrast, other conditions listed, such as dehydration, postoperative recovery, and hypotension, do not represent absolute contraindications. In fact, Hetastarch can sometimes be beneficial in these scenarios to quickly restore intravascular volume and improve hemodynamic stability. Therefore, understanding the specific risks associated with coagulopathy reinforces why it is crucial to avoid Hetastarch in these patients.

Hetastarch, also known as Hespan, is a volume expander that is often used in situations requiring plasma volume expansion. However, it is contraindicated in patients with coagulopathy because it can impair normal blood clotting mechanisms. Coagulopathy refers to a condition in which the blood’s ability to clot is severely reduced, leading to an increased risk of bleeding.

When administering Hetastarch in such patients, there is a significant risk that the medication could exacerbate bleeding complications by further interfering with coagulation processes. The synthetic colloid effect of Hetastarch can dilute clotting factors or interfere with platelet function, creating a hazardous situation for individuals already susceptible to bleeding due to an underlying coagulopathy.

In contrast, other conditions listed, such as dehydration, postoperative recovery, and hypotension, do not represent absolute contraindications. In fact, Hetastarch can sometimes be beneficial in these scenarios to quickly restore intravascular volume and improve hemodynamic stability. Therefore, understanding the specific risks associated with coagulopathy reinforces why it is crucial to avoid Hetastarch in these patients.